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Abstract
Context: Highly active antiretroviral treatment (HAART) usage in India is escalating. With the government of India launching
the free HAART rollout as part of the "3 by 5" initiative, many people living with HIV/AIDS (PLHA) have been able to gain access
to HAART medications. Currently, the national HAART centers are located in a few district hospitals (in the high- and medium-
prevalence states) and have very stringent criteria for enrolling PLHA. Patients who do not fit these criteria or patients who are
too ill to undergo the prolonged wait at the government hospitals avail themselves of nongovernment organization (NGO)
services in order to take HAART medications. In addition, the government program has not yet started providing second-line
HAART (protease inhibitors). Hence, even with the free HAART rollout, NGOs with the expertise to provide HAART continue
to look for funding opportunities and other innovative ways of making HAART available to PLHA. Currently, no study from
Indian NGOs has compared the direct and indirect costs of solely managing opportunistic infections (OIs) vs HAART.
Objective: Compare direct medical costs (DMC) and nonmedical costs (NMC) with 2005 values accrued by the NGO and
PLHA, respectively, for either HAART or exclusive OI management.
Study design: Retrospective case study comparison.
Setting: Low-cost community care and support center  Freedom Foundation (NGO, Bangalore, south India).
Patients: Retrospective analysis data on PLHA accessing treatment at Freedom Foundation between January 1, 2003 and
January 1, 2005. The HAART arm included case records of PLHA who initiated HAART at the center, had frequent follow-up,
and were between 18 and 55 years of age. The OI arm included records of PLHA who were also frequently followed up, who
were in the same age range, who had CD4+ cell counts < 200/microliter (mcL) or an AIDS-defining illness, and who were not
on HAART (solely for socioeconomic reasons). A total of 50 records were analyzed. Expenditures on medication,
hospitalization, diagnostics, and NMC (such as food and travel for a caregiver) were calculated for each group.
Results: At 2005 costs, the median DMC plus NMC in the OI group was 21,335 Indian rupees (Rs) (mean Rs 24,277/-) per
patient per year (pppy) (US $474). In the HAART group, the median DMC plus NMC was Rs 18,976/- (mean Rs 21,416/-) pppy
(US $421). Median DMC plus NMC pppy in the OI arm was Rs 13623.7/- paid by NGO and Rs 1155/- paid by PLHA. Median
DMC and NMC pppy in the HAART arm were Rs 1425/- paid by NGO and Rs 17,606/- paid by PLHA.
Conclusion: Good health at no increased expenditure justifies providing PLHA with HAART even in NGO settings.
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Introduction
With over 5 million people living with HIV/AIDS (PLHA),
India has the world's second highest number of HIV-pos-
itive cases.[1] With their average income majority, PLHA
find it difficult to procure highly active antiretroviral treat-
ment (HAART), despite the presence of generic drugs.
Until a few years ago, financial constraints led to focusing
on opportunistic infections (OI). This affects the mortality
and morbidity due to OIs, but the need for HAART
remains inevitable.[2-7]
The national free HAART program, which began in 2004
as part of the "3 by 5" initiative, targets a goal of reaching
100,000 eligible PLHA over 5 years.[8] In 20042005, a
total of 25 HAART centers were functioning in India (17
in the 6 high-prevalence states, 2 in the national capital,
and the remainder in the medium-prevalence states). The
program goal was to initiate HAART in 25,000 PLHA in
that time period. The national estimate for AIDS cases in
India for August 2006 was 124,995.[9,10]
Currently, many nongovernment organizations (NGOs)
send PLHA to the government centers to obtain HAART.
Very few NGOs provide HAART to PLHA and have the
expertise to do so. Many NGOs do not take on the respon-
sibility of initiating free HAART therapy for PLHA because
lack of adequate funds could affect sustainability. The
national rollout is currently located in a few district hos-
pitals and is undergoing a scale-up with more government
centers due to open in the course of 2006. The govern-
ment HAART centers' criteria for enrolling PLHA are
CD4+ cell counts of ≤ 200 cells/microliter (mcL) and/or
clinical stage III or IV according to the World Health
Organization and National AIDS Control Organization
(NACO) guidelines.[11] The government HAART centers
request the presence of a family member to take responsi-
bility of ensuring that the PLHA maintain follow-up.
There are patients who are unable to avail themselves of
the government's free HAART program, including those
with CD4+ cell counts between 200 and 250/mcL whose
quality of life has been affected due to recurrent illness
and patients who are too ill to undergo the prolonged
wait at the government hospitals. In addition, the govern-
ment program has not yet started providing second-line
HAART, which in India means protease inhibitors.
In the NGO sector, HAART depends on the PLHA's socio-
economic condition or available funding. Hence, NGOs
with the expertise to provide HAART continue to raise
funds and look at innovative ways of making HAART
medications available to those PLHA who are unable to
access the government services. In addition, there are
many PLHA who would prefer to pay for their medica-
tions and go to the private/NGO sector for various rea-
sons, such as confidentiality, convenience, less time-
consuming, and more personalized attention. Some of
the NGOs that have strong HAART programs are able to
obtain concessions on bulk purchase of HAART drugs,
and these concessions are in turn passed on to the PLHA.
A pertinent question for NGOs in such settings would be
in regard to costs incurred by the organization and the
PLHA for HAART/OI management vis-a-vis overall benefit
to the patient. High-income countries with well-function-
ing public health systems indicate that providing HAART
is not a burden on the economy.[12-14] However, lessons
from countries, such as Nigeria, show that a weak public
health system can retard the HAART program.[15] This
study compares the costs incurred for OI management
with the cost of providing HAART by this NGO and by
PLHA.
Materials and methods
Setting
Freedom Foundation is an Indian NGO with many cent-
ers that provide care and support for PLHA. This study was
conducted in Bangalore, India (capital of Karnataka state
and one of the high-prevalence states), where their head
office is located.
The NGO includes a 60-bed inpatient (IP) facility of
which 25 beds are for children. An outpatient (OP) clinic
functions 5 days a week. The personnel include a project
coordinator, 1 medical officer, 6 nurses (1 on night shift),
1 lab technician, 4 counselors, and 12 members in other
supportive capacities. At the time of this study, the labora-
tory was equipped to handle HIV rapid spot tests, Vene-
real Disease Research Laboratory test (VDRL), hepatitis B
surface antigen (HBsAg) rapid test, sputum microscopy,
and basic biochemistry tests, such as liver and renal func-
tion tests, hemoglobin, and total and differential white
blood cell counts. At the time of this study, advanced tests,
such as CD4+ T lymphocyte counts and x-rays, were
referred out. Between April 2003 and April 2004, there
were 629 (IP + OP) new registrations, 407 readmissions,
and 2350 OP follow-up visits.[16] Among the new regis-
trations that year, 398 (63.3%) were men; 196 (31.1%)
were women; 33 (5.2%) were children; and 2 (0.4%) were
eunuchs. Ninety deaths were recorded at the center. Five
hundred seventy-two (91%) new registrations were
infected via unprotected heterosexual intercourse.
The majority of PLHA accessing care at the Freedom Foun-
dation NGO at Bangalore are from lower socioeconomic
strata. Among new registrations in 20032004, 151 (24%)
were daily wage workers; 75 (12%) were agricultural lab-
orers; 122 (19.4%) were housewives; and remaining peo-
ple had other occupations. Most can't afford prolonged
medical care. The NGO receives an annual government
grant that includes the cost of certain categories of essen-
tial drugs that play a supportive role in the management
of OIs. Some of the antibiotics provided included tetracy-Journal of the International AIDS Society 2006, 8:24 http://www.jiasociety.org/content/8/4/24
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cline, tinidazole, metronidazole, and cotrimoxazole.
Other more specific antibiotics/antiviral drugs that are
used to treat or prevent other OIs were not included.[17]
The NGO has been provided with tuberculosis (TB) med-
ication by the Revised National TB Control Program
(RNTCP). Other government support includes (1) food
for IPs, (2) one-time infrastructure support, (3) ongoing
support for remuneration for the staff of the NGO, and
(4) an allowance for rent, water, and electricity. With the
government grant, about 750 patients can get IP care at
our NGO (assuming that a patient gets admitted for 1015
days), and this accounts for about 25% of the total
number of PLHA who received medical care in 20032004.
Donor funding provides treatment for the remaining
patients (approximately 2500 individuals). Separate
funds are raised by our NGO in order to provide free
HAART to a few PLHA, especially all eligible children,
widowed mothers, and destitute people. Nearly 1 in 5 of
the adults on HAART (17.6%; 23 patients among 131) at
the center during the study period were supported
through these donations. Between 2003 and 2004, 31
PLHA were started on HAART at the center. Government
grants do not support HAART at this NGO, and patients
who enroll under NGO HAART programs (for the reasons
stated above) have to either pay for their own HAART
(medicines and laboratory monitoring) or receive contin-
ued support from the NGO.
Patients
Purposive sampling[18] of PLHA treated at the center
between January 1, 2003 and January 1, 2005 was done in
order to identify patient records in the HAART arm. Pur-
posive sampling was used to select records of patients who
were on HAART and being followed up at regular intervals
because the main aim was to compare costs of sustaining
HAART with the cost of providing OI treatment. The
HAART arm included case records of clients who initiated
HAART at the center, regularly followed up for more than
1 year, for whom complete documentation of records was
available, between 18 and 55 years age and still alive.
These were matched with cases in the OI arm; matching
criteria included age and sex, for whom complete docu-
mentation of records was available. Overall, patients in
the OI arm were of a similar age group, had CD4+ cell
counts < 200 cells/mcL or an AIDS-defining illness, and
were not on HAART solely for socioeconomic reasons. All
PLHA in the OI arm had at least 1 hospital admission. A
total of 50 records were analyzed. Costs for medication,
hospitalization, laboratory investigations, and nonmedi-
cal costs (NMC; caregiver expenses and travel) were con-
sidered. Twenty-five case records were selected for each
arm. The HAART arm included 3 cases with pre-HAART
CD4+ cell counts above 200 cells/mcL. Treatment of those
patients was started when the protocol for initiating
HAART was a CD4+ cell count < 500 cells/mcL. Exclusion
criteria in both groups were age, not eligible for HAART as
per NACO guidelines, or poor follow-up.
Analysis
Analysis of economic resource utilization in both arms
was based on case record assessment. Treatment expendi-
ture was divided into direct medical costs (DMC) and
NMC.[19] Variables considered for DMC were medicines,
laboratory and other diagnostic tests, service providers'
fees (although no fee is charged to the PLHA it has been
included in the calculations in order to have more clarity
in the results), costs for hospitalization (totally borne by
the NGO), and food. (The patients' food is provided free,
whereas the caregivers' food may be paid for either by the
NGO or by PLHA). NMC included travel for PLHA and
food and travel for a caregiver. The cost was calculated for
1 year in all arms.
The data analysis was done with SPSS software.
Patients consented to the use of data in their records.
Results
Baseline Data
A total of 50 patient files were selected, 25 in the HAART
arm and 25 in the OI arm. Table 1 provides baseline
details of those included in the study, and Table 2 pro-
vides clinical features of PLHA in the OI and HAART arms.
There were socioeconomic differences between the
groups, which are discussed subsequently.
Occupation and income
Prior to entering the treatment program at the Freedom
Foundation community care and support facility, PLHA
in the OI arm had the following occupations: Ten (40%)
were laborers; 5 (20%) were drivers, 4 (16%) were unem-
ployed; and the remaining people had other professions.
In the male HAART arm, before starting HAART, 8 (32%)
of the male patients were self-employed; 5 (20%) were
unemployed, and the remaining men had other occupa-
tions. After a year on HAART, 5 (20%) men were self-
employed; 3 (12%) were unemployed; and the rest of the
men had other occupations. In the female HAART group,
4 (50%) were housewives before initiating treatment;
12.5% were daily wage laborers; and 25% had other forms
of employment. About 12.5% of women were in very
small businesses that generated very little income; the per-
son involved usually owns a small shop where he/she
would sell things, such as cigarettes and chocolates.  pos-
sibly even small-time fruit vendors and roadside flower
sellers. in India, women string together jasmine, mari-
gold, and other such flowers, which are then sold. After
HAART 3 (37.5%) continued as housewives; 3 (37.5%)
had other occupations; and 2 (25%) were daily wage lab-
orers.Journal of the International AIDS Society 2006, 8:24 http://www.jiasociety.org/content/8/4/24
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Drug regimens
In the HAART arm, 16 (64%) were on either zidovudine
or stavudine plus lamivudine and nevirapine, and the
remaining people were on other regimens. HAART was
started at the NGO itself. Regimens varied depending on
affordability, drug reaction, and the presence of tubercu-
losis. Cotrimoxazole prophylaxis for Pneumocystis carinii
pneumonia was used for all patients in both arms.
Clinical Outcomes
Twenty-two PLHA (88%) in the OI arm and 9 (36%) in
the HAART arm had multiple OIs and/or concomitant
infections, which merited admission to the Freedom
Foundation care and support facility during the study
period. Table 3 lists each infection once regardless of the
number of episodes. PLHA in the OI arm had a median IP
stay of 52 days of admission and 9 episodes of OP (mean,
9.2 ± 4.2) follow-up. There were no admissions in PLHA
in the HAART arm, and there were 12 episodes of follow-
up (mean, 10.96 ± 2.92).
Economic Comparisons
DMC
DMC included drugs, hospital costs, and tests used in
diagnosis and monitoring. Table 4 shows the total DMC
incurred by the NGO and PLHA, respectively, for both
arms.
The median cost of drugs for OI management and sup-
portive treatment in the OI arm was Rs 4016/per person
Table 1: Baseline Demographic Characteristics of Persons Living With HIV/AIDS
Parameter Characteristic OI Arm HAART Arm
Age, median 31 years 34 years
Sex Woman 7 (32%) 7 (32%)
Man 18 (68%) 18 (68%)
Marital status Single 6 (24%) 6 (24%)
Married 16 (64%) 14 (56%)
Widowed 3 (12%) 5 (20%)
Geographic location In Bangalore 10 (40%) 16 (64%)
Outside Bangalore 15 (60%) 9 (36%)
Months enrolled in study, mean 12 ± 1.6 12 ± 0.0
Income per day prior to OI treatment/HAART, median Rs. 33/day* Rs 133/day
*US $1 = approximately Rs 45 during the study period in 2005
Rs = rupees; OI = opportunistic infection management only; HAART = highly active antiretroviral therapy
Table 2: Baseline Clinical Features
OI Arm (n = 25) HAART Arm (n = 25)
HIV disease stage, number (%)
Asymptomatic* 0 (0%) 4 (16%)
Stage III 4 (16%) 7 (28%)
Stage IV 21 (84%) 14 (56%)
CD4+ cell counts, median cells/mcL (SD) 74 (57.56) 135 (101.47)
Mean period since HIV detection, months 22.8 33.9
*Asymptomatic with CD4+ cells < 200 cells/microliter (mcL)
OI = opportunistic infection management only; HAART = highly active antiretroviral therapyJournal of the International AIDS Society 2006, 8:24 http://www.jiasociety.org/content/8/4/24
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per year (pppy); this was completely borne by the NGO
with no PLHA contribution. The median PLHA-borne
expenditure on HAART was Rs 15,768/pppy. Median cost
incurred by the NGO to provide free HAART to 5 PLHA
was Rs 10,585/pppy. Within the HAART arm, the median
expenditure for supportive drugs was Rs 556/pppy for the
NGO and Rs 438/pppy for the PLHA.
Hospital costs included food, laundry, consultants' fees,
and overhead. PLHA in both arms were admitted for OIs,
drug reactions, and palliative care and didn't contribute
toward the expense of hospitalization. The median NGO-
borne costs for hospitalization were Rs 6105/pppy for the
OI arm and Rs 300/pppy for the HAART arm.
Laboratory and other diagnostic or monitoring tests
included sputum for acid-fast bacilli, x-ray, CD4+ cell
counts, liver function tests, hemoglobin, and other inves-
tigations as required. CD4+ cell count was available to all
patients at subsidized rates and was done every 36
months. The median investigation cost in the OI arm was
Rs 1160/pppy, of which the NGO-borne median cost was
Rs 755/pppy. In the HAART arm, the median cost of inves-
tigations was 1400/pppy, of which NGO-borne median
cost was Rs 713/pppy.
Indirect NMC
NMC included travel for patients and caregivers, food for
patients and caregivers during travel, and caregivers' food
during hospitalization.
In both arms, often the caregivers' food was provided by
the NGO. Median NMC in the OI arm was Rs 7370/pppy,
of which the median Rs 3640/pppy was NGO-borne. In
Table 3: Opportunistic Infections and Concomitant Diseases
Infection, Number (%) OI Arm HAART Arm
Tuberculosis 22 (88%) 11 (44%)
Oral Candida 17 (68%) 6 (24%)
Recurrent diarrhea 8 (32%) 6 (24%)
Cryptococcal meningitis 5 (20%) 2 (8%)
Other: Herpes zoster, toxoplasmosis, Pneumocystis carinii pneumonia, Cytomegalovirus 7 (28%) 4 (16%)
OI = opportunistic infection management only; HAART = highly active antiretroviral therapy
Table 4: Total Direct Medical Costs Incurred by the Nongovernment Organization (OI Arm, n = 25) and Persons Living With AIDS 
(HAART Arm, n = 25)
Type of Direct 
Cost
OI Arm Total 
NGO-Borne 
Costs,
 Rs (% of Total 
Study-Arm 
Cost)
OI Arm Total 
PLHA-Borne 
Costs, 
Rs  (% of Total 
Study-Arm 
Cost)
Total Cost in OI 
Arm, 
Rs (% of Total 
Study-Arm 
Cost)
HAART Arm 
Total NGO-
Borne Costs, 
Rs (% of Total 
Study-Arm 
Cost)
HAART Arm 
Total PLHA-
Borne Costs,
 Rs (% of Total 
Study-Arm 
Cost)
Total Cost in 
HAART Arm, 
Rs (% of Total 
Study-Arm 
Cost)
Drugs 119,008
(19.6%)
3028
(0.49%)
122,036
(20.11%)
*69,040
(12.9%)
380,241
(71.01%)
449,282
(83.91%)
Hospital care 226,460
(37.3%)
0
(0%)
226,460
(37.3%)
23,525
(4.39%)
0
(0%)
23,525
(4.39%)
Investigations 21,860
(3.6%)
19,365
(3.2%)
41,225
(7%)
665
(1.24%)
27,205
(5.08%)
33,870
(6.33%)
Total cost 367328
(60.52%)
22,393
(3.69%)
389,721
(64.21%)
99,230
(18.53%)
407,446
(76.09%)
506,677
(94.63%)
Mean 14,693 896 15,588.8 3969 16,298 20,267
Median 10,495 100 13,448 1425 17,366 18,646Journal of the International AIDS Society 2006, 8:24 http://www.jiasociety.org/content/8/4/24
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the HAART arm, the median NMC pppy was Rs 240/-, of
which the median Rs 200/- was PLHA-borne. Table 5
shows total DMC and NMC in both arms. Total costs for
1 year were similar: median Rs 20,040/- (mean, Rs
23,402/-) pppy in the OI arm and median Rs 18,976/-
(mean, Rs 21,416/-) in the HAART arm.
After the end of the study period of 1 year in the OI arm,
7 (28%) were started on HAART. After the end of the study
period, 8 (32%) expired from OIs; 5 (20%) were still
alive; and 5 (20%) were lost to follow-up. All PLHA in the
HAART arm were followed after the study period. All
patients were alive during the study period (both arms).
Discussion and Conclusion
The study population was small. Sampling of records on
the basis of selected adds bias. Those on HAART were orig-
inally from a higher income bracket and hence could sus-
tain their medications. Better socioeconomic conditions
indicated by the ability to bear these costs would imply
better access to healthcare, monitoring of CD4+ cell
counts, appropriate initiation of HAART, and better fol-
low-up. The pretreatment CD4+ cell counts in the HAART
arm were greater than those in the OI arm. Baseline health
status is bound to affect all subsequent costs  hospitaliza-
tion, drugs, etc. The description of costs applies to this
NGO only. Costs may vary in other settings depending on
drug costs and administrative policies. The cost of pro-
tease inhibitor-based regimens was not considered
because PLHA who were accessing care at the center were
still on treatment with nucleosides and nonnucleoside
reverse transcriptase inhibitors.
Although this study lacks sufficient numbers for signifi-
cant conclusions, the similarity between costs for exclu-
sive OI treatment and HAART is apparent regardless of
who pays  NGO or patient. Our observations concur with
findings from other international studies. African studies
indicated that unaffordability prevents PLHA from taking
HAART.[20] (Although Indian generics are available in
foreign countries for $140 pppy, in India it costs nearly
$148 pppy.) Studies from Tanzania have shown that
PLHA who pay for their HAART medication have a higher
risk of nonadherence.[21] Studies from Brazil indicated
that supporting PLHA with domestically produced
HAART results in a 48% cost reduction per patient. Brazil-
ian and African studies showed that HAART reduces the
average number of annual hospitalizations and hence
result in considerable cost savings.[22-24]
In our study, the NGO contribution to DMC and NMC
was 83% in the OI arm and 24% for the HAART arm. Hos-
pitalization costs for PLHA could be double than for HIV-
uninfected people.[25,26] Studies in Italy showed that
74% of medical costs for PLHA were for HAART;[27] our
study indicated 80%.
It is known that AIDS results in loss of activity and
decreased productivity. HAART, however, helps sustain
economic productivity and reduces absenteeism.[28-30]
Increased longevity has other implications, such as reduc-
tion in number of orphans, thereby reducing financial
strain on the government. These factors were, however,
not considered in this study because it was a case record
analysis based on purposive sampling, and the patients in
the OI arm were not available for ascertaining informa-
tion.
Observations from Nigeria indicated that a weak public
health sector weighed down by high drug costs, inade-
Table 5: Direct Medical and Nonmedical Costs Incurred by the NGO and PLHA in 1 year (OI Arm, n = 25; HAART Arm, n = 25)
Cost OI Arm NGO-
Borne Rs (% of 
Total 
Study-Arm 
Cost)
OI Arm Patient-
Borne Rs (% of 
Total 
Study-Arm 
Cost)
Total Costs OI 
Arm Rs (% of 
Total 
Study-Arm 
Cost)
HAART Arm 
NGO-Borne Rs 
(% of Total 
Study-Arm 
Cost)
HAART Arm 
Patient-Borne 
Rs (% of Total 
Study-Arm 
Cost)
Total Costs 
HAART Arm 
Rs (% of Total 
Study-Arm 
Cost)
Direct medical 
costs
367328
60.52%
22,393
3.69%
389721
64.21%
99,230
18.53%
407,446
76.09%
506,677
(94.63%)
Nonmedical 
costs
134,330
(22.1%)
82,870
(13.65%)
217,200
(35.7%)
4130
(0.77%)
24,610
(4.6%)
28,740
(5.37%)
Total 501,658
(82.7%)
105,263
(17.34%)
606,921 103,360
(23.92%)
432,056
(80.70%)
535,417
Mean 20,066.34 4211 24,277 4134 17,282 21,416
Median 13,623.7 1155 21,335 1425 17,606 18,976
NGO = nongovernment organization; PLHA = persons living with AIDS; OI = opportunistic infection management only; HAART = highly active 
antiretroviral therapy; Rs = rupeesJournal of the International AIDS Society 2006, 8:24 http://www.jiasociety.org/content/8/4/24
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quate and/or intermittent drug supplies, lack of trained
healthcare providers, inadequate patient monitoring, and
inconsistent selection criteria can weaken HAART pro-
grams.[31,32]
In conclusion, although the situation in India merits scal-
ing up HAART, resource constraints make it imperative for
the government and NGO sector to unite and explore
more sustainable programs.
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